Tokyo – This Friday was announced by a group of Japanese researchers transplanted induced pluripotent stem cells (iPS) in the brain of the patient suffering from the disease Parkinson's disease the first such study in the world.
The Kyoto University team injected 2.4 million iPS cells – able to produce any type of cells – left on the brain for three hours, which was done in October.
A man, about 50 years old, has been well tolerated and will remain monitored for two years, announced the Kyoto University.
If there is a problem in the next six months, researchers will implant 2.4 million additional cells, this time on the right side of the brain.
These iPS cells from healthy donors need to be developed in the neurons that produce them dopamine, neurotransmitter, which interfere with motor skills control.
The Kyoto University announced in July that it would conduct clinical research with seven people aged 50-69.
Parkinson's disease is characterized by neuronal degeneration with gradually deteriorating symptoms such as tremor, muscle stiffness and loss of body movement.
According to the Global Fund for Disease Control, it affects more than 10 million people in the world Parkinson's disease American. Currently available therapies "improve symptoms without reducing disease progression" explains the basis.
The purpose of the new investigation is to eliminate the evil.
Before human clinical study, an experiment was conducted on human-derived stem cell monkeys, which made it possible to improve the mobility of a primates with Parkinson's motion, according to a study published at the end of August 2017 in the science journal Nature.
For two years, the survival rate of transplanted cells was carefully monitored by injection into the brain of primates and no tumor was detected.
Inductive pluripotent stem cells (iPS) adult cells are reduced to their almost embryonic state to produce four genes (usually inactive adults). This genetic manipulation returns the ability to create any cell according to the body where they are transplanted.
Unlike stem cells derived from human embryos, the use of iPS cells does not cause significant ethical problems.